1. Home
  2. WVE vs KOD Comparison

WVE vs KOD Comparison

Compare WVE & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WVE
  • KOD
  • Stock Information
  • Founded
  • WVE 2012
  • KOD 2009
  • Country
  • WVE Singapore
  • KOD United States
  • Employees
  • WVE N/A
  • KOD N/A
  • Industry
  • WVE Biotechnology: Pharmaceutical Preparations
  • KOD Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • WVE Health Care
  • KOD Health Care
  • Exchange
  • WVE Nasdaq
  • KOD Nasdaq
  • Market Cap
  • WVE 915.6M
  • KOD 795.5M
  • IPO Year
  • WVE 2015
  • KOD 2018
  • Fundamental
  • Price
  • WVE $7.35
  • KOD $20.86
  • Analyst Decision
  • WVE Strong Buy
  • KOD Buy
  • Analyst Count
  • WVE 14
  • KOD 7
  • Target Price
  • WVE $20.50
  • KOD $22.29
  • AVG Volume (30 Days)
  • WVE 3.6M
  • KOD 774.7K
  • Earning Date
  • WVE 11-10-2025
  • KOD 11-13-2025
  • Dividend Yield
  • WVE N/A
  • KOD N/A
  • EPS Growth
  • WVE N/A
  • KOD N/A
  • EPS
  • WVE N/A
  • KOD N/A
  • Revenue
  • WVE $109,230,000.00
  • KOD N/A
  • Revenue This Year
  • WVE N/A
  • KOD N/A
  • Revenue Next Year
  • WVE $6.24
  • KOD N/A
  • P/E Ratio
  • WVE N/A
  • KOD N/A
  • Revenue Growth
  • WVE 103.75
  • KOD N/A
  • 52 Week Low
  • WVE $5.28
  • KOD $1.92
  • 52 Week High
  • WVE $16.38
  • KOD $22.14
  • Technical
  • Relative Strength Index (RSI)
  • WVE 49.41
  • KOD 61.97
  • Support Level
  • WVE $6.60
  • KOD $19.25
  • Resistance Level
  • WVE $7.27
  • KOD $21.95
  • Average True Range (ATR)
  • WVE 0.53
  • KOD 1.79
  • MACD
  • WVE -0.04
  • KOD -0.01
  • Stochastic Oscillator
  • WVE 51.78
  • KOD 78.44

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

About KOD Kodiak Sciences Inc

Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.

Share on Social Networks: